Clinical Trials Browser

Phase 2 × Suspended × tazemetostat × Clear all

NCT06575686 2026-01-21

Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

Phase 2 Suspended

Lymphoma, Follicular

NCT06692452 2026-01-07

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

Phase 2 Suspended

Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, T-Cell, Peripheral, Enteropathy-Associated T-Cell Lymphoma